Evidence map›Paper›PMID 38148815›Full record

ArticleHeliyon2024

Comparison of the efficacy of combined budesonide and fexofenadine versus combined fluticasone propionate and fexofenadine on the expression of class-4 semaphorins and their receptors in the peripheral blood cells of patients with allergic rhinitis.

Gelayol Asadi, Parisa Feizollahi, Misagh Rajabinejad, Sara Falahi, Fatemeh Rezaei Varmaziar, Elham Faryadi, Ali Gorgin Karaji, Farhad Salari, Alireza Rezaiemanesh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Gelayol AsadiStudent Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Parisa FeizollahiDepartment of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Misagh RajabinejadDepartment of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Sara FalahiStudent Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Fatemeh Rezaei VarmaziarStudent Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Elham FaryadiStudent Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ali Gorgin KarajiDepartment of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Farhad SalariDepartment of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Alireza RezaiemaneshDepartment of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Kermanshah University of Medical Sciences · IRMazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Allergic rhinitis (AR) is a common immunoglobulin (Ig) E-mediated disease. This study aimed to evaluate the gene expression levels of class 4 semaphorins and their receptors in AR patients before and after treatment with budesonide and fexofenadine (B/F) compared to fluticasone propionate and fexofenadine (FP/F). Methods: In this study, 29 AR patients (age 34.4 ± 1.2 years, 18 men and 11 women) were treated with B/F, and 24 AR patients (age 32.8 ± 1.9 years, 15 men and 9 women) were treated with FP/F for one month. Before and after treatment, peripheral blood samples were taken from patients. The expression levels of Results: The expression levels of Conclusion: In conclusion, concomitant use of fexofenadine and fluticasone propionate reduced

Indexed as

Allergic rhinitisBudesonideClass 4 semaphorinsFexofenadineFluticasone propionatePlexin

Identifiers

PMID38148815
PMCPMC10750067
OpenAlexW4389096895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.